Refining a numerical model for device-induced thrombosis and investigating the effects of non-Newtonian blood models

Ling, Yang; Tobin, Nicolas; Manning, Keefe B.

doi:10.1016/j.jbiomech.2021.110393

Cited by 14 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from the latest BSF experiment which used human blood shows the thrombi is a triangular ramp shape ( Yang et al, 2020 ). While a quasi-triangular slope shape is observed in our simulation results, which is similar to the previous computational report ( Yang et al, 2021 ). There may be three reasons for the difference in thrombus shape.…”

Section: Discussionsupporting

confidence: 92%

“…Recently, Yang et al (2020) provided experimental data for device-induced thrombosis using bovine and human blood in the same backward-facing step model as Taylor et al (2014) . Besides, Yang et al (2021) analyzed the thrombosis formation for non-Newtonian blood by developing the device-induced thrombosis model proposed by Taylor et al (2016b) . These studies have laid a good foundation for macroscopic thrombosis research.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Computational Prediction of Thrombosis in Food and Drug Administration’s Benchmark Nozzle

2022

View full text Add to dashboard Cite

Thrombosis seriously threatens human cardiovascular health and the safe operation of medical devices. The Food and Drug Administration’s (FDA) benchmark nozzle model was designed to include the typical structure of medical devices. However, the thrombosis in the FDA nozzle has yet not been investigated. The objective of this study is to predict the thrombus formation process in the idealized medical device by coupling computational fluid dynamics and a macroscopic hemodynamic-based thrombus model. We developed the hemodynamic-based thrombus model by considering the effect of platelet consumption. The thrombus model was quantitatively validated by referring to the latest thrombosis experiment, which was performed in a backward-facing step with human blood flow. The same setup was applied in the FDA nozzle to simulate the thrombus formation process. The thrombus shaped like a ring was firstly observed in the FDA benchmark nozzle. Subsequently, the accuracy of the shear-stress transport turbulence model was confirmed in different turbulent flow conditions. Five scenarios with different Reynolds numbers were carried out. We found that turbulence could change the shape of centrosymmetric thrombus to axisymmetric and high Reynolds number blood flow would delay or even prevent thrombosis. Overall, the present study reports the thrombosis process in the FDA benchmark nozzle using the numerical simulation method, and the primary findings may shed light on the effect of turbulence on thrombosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Computational Prediction of Thrombosis in Food and Drug Administration’s Benchmark Nozzle

2022

View full text Add to dashboard Cite

show abstract

“…The parameter values used in the various equations of the Taylor model are given in Table 1 of Taylor et al 12 Taylor et al 12 also performed blood-loop experiments to train and validate the derived model. Yang et al 13 later made modifications to the Taylor 12 model, in particular incorporating a different model for chemical platelet activation, since the Taylor 12 model never reached high enough levels of ADP to lead to chemical platelet activation. The Yang et al 13 chemical activation model is used in the current iteration of the thrombosis model, and is given in Equation (11).…”

Section: Taylor Model and Modifications From Yang Et Almentioning

confidence: 99%

“…Yang et al 13 later made modifications to the Taylor 12 model, in particular incorporating a different model for chemical platelet activation, since the Taylor 12 model never reached high enough levels of ADP to lead to chemical platelet activation. The Yang et al 13 chemical activation model is used in the current iteration of the thrombosis model, and is given in Equation (11). Yang et al 13 also investigated the use on non-Newtonian viscosity models, which are not incorporated into the current study.…”

Section: Taylor Model and Modifications From Yang Et Almentioning

confidence: 99%

“…Taylor et al 12 adapted this model with a material‐specific thrombus susceptibility potential term, replacing the viscoelastic model with a Brinkman model to couple the thrombus and the flow, and trained their model on experimental data of clot growth in a backward‐facing step geometry. Yang et al 13 explored modifications to the Taylor et al 12 model to make corrections to the biochemical activation and investigate the impact of non‐Newtonian constitutive models on thrombus growth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Toward modeling thrombosis and thromboembolism in laminar and turbulent flow regimes

Tobin

Manning

2022

Numer Methods Biomed Eng

Self Cite

View full text Add to dashboard Cite

Thrombosis and thromboembolism are deadly risk factors in blood-contacting biomedical devices, and in-silico models of thrombosis are attractive tools to understand the mechanics of these processes, though the simulation of thromboembolism remains underdeveloped. The purpose of this study is to modify an existing computational thrombosis model to allow for thromboembolism and to investigate the behavior of the modified model at a range of flow rates.The new and existing models are observed to lead to similar predictions of thrombosis in a canonical backward-facing step geometry across flow rates, and neither model predicts thrombosis in a turbulent flow. Simulations are performed by increasing flow rates in the case of a clot formed at lower flow to induce embolization. While embolization is observed, most of the clot breakdown is by shear rather than by breakup and subsequent transport of clotted material, and further work is required in the formulation and validation of embolization. This model provides a framework to further investigate thromboembolization.

show abstract

Numerical simulation and experimental validation of thrombolytic therapy for patients with venous isomer and normal venous valves

Lin

Zhang

et al. 2023

Numer Methods Biomed Eng

View full text Add to dashboard Cite

Thrombus is an extremely dangerous factor in the human body that can block the blood vessel. Once thrombosis happens in venous of lower limbs, local blood flow is impeded. This leads to venous thromboembolism (VTE) and even pulmonary embolism. In recent years, venous thromboembolism has frequently occurred in a variety of people, and there is no effective treatment for patients with different venous structures. For the patients with venous isomer with single valve structure, we establish a coupled computational model to simulate the process of thrombolysis with multi‐dose treatment schemes by considering the blood as non‐Newtonian fluid. Then, the corresponding in vitro experimental platform is built to verify the performance of the developed mathematical model. At last, the effects of different fluid models, valve structures and drug doses on thrombolysis are comprehensively studied through numerical and experimental observations. Comparing with the experimental results, the relative error of blood boosting index (BBI) obtained from non‐Newtonian fluid model is 11% smaller than Newtonian fluid. In addition, the BBI from venous isomer is 1300% times stronger than patient with normal venous valve while the valve displacement is 500% times smaller. As consequence, low eddy current and strong molecular diffusion near the thrombus in case of isomer promote thrombolysis rate up to 18%. Furthermore, the 80 μM dosage of thrombolytic drugs gets the maximum thrombus dissolution rate 18% while the scheme of 50 μM doses obtains a thrombolysis rate of 14% in case of venous isomer. Under the two administration schemes for isomer patients, the rates from experiments are around 19.1% and 14.9%, respectively. It suggests that the proposed computational model and the designed experiment platform can potentially help different patients with venous thromboembolism to carry out clinical medication prediction.

show abstract

Refining a numerical model for device-induced thrombosis and investigating the effects of non-Newtonian blood models

Cited by 14 publications

References 26 publications

Computational Prediction of Thrombosis in Food and Drug Administration’s Benchmark Nozzle

Computational Prediction of Thrombosis in Food and Drug Administration’s Benchmark Nozzle

Toward modeling thrombosis and thromboembolism in laminar and turbulent flow regimes

Numerical simulation and experimental validation of thrombolytic therapy for patients with venous isomer and normal venous valves

Contact Info

Product

Resources

About